STERIS plc
Mentor, Ohio, United States · Biotechnology, Health Care
STERIS plc is a global leader in providing infection prevention and other procedural products and services. The company focuses on improving patient outcomes and healthcare efficiency. With its wide range of innovative solutions, STERIS serves various markets, including healthcare and pharmaceutical industries.
Key facts
- Headquarters
- Mentor, Ohio, United States
- Employees
- 18,000
- Industries
- Biotechnology, Health Care
- Status
- Public (STE)
- Website
- www.steris.com
- Company page
Recent activity at STERIS plc
- : SEC 8-K (2.05):
- : SEC 8-K (1.01): On November 4, 2026, STERIS plc, along with STERIS Corporation, STERIS Limited, and STERIS Irish FinCo Unlimited Company, entered into a New Revolving Credit Agreement providing for a $1,600 million revolving credit facility. This new agreement replaces the existing revolving credit agreement dated October 7, 2024. The facility allows for various types of borrowings, including up to $800 million in incremental commitments, maturing on November 4, 2031. Customary covenants and restrictions concerning indebtedness and liens are included, with varying interest rates based on defined benchmarks.
- : STERIS to acquire Xodus Medical for $2.1B
- : SEC 8-K (1.01): On October 11, 2026, STERIS Corporation, a subsidiary of STERIS plc, entered into a Purchase and Sale Agreement with Craig E. Kaforey and Mark A. Kaforey to acquire all equity interests of Xodus Medical, Inc. for $2.1 billion in cash at closing, with an additional earnout of up to $150 million based on future performance. The acquisition, expected to close by December 31, 2026, will primarily be financed through a bridge facility worth up to $2.0 billion from JPMorgan and Goldman Sachs. The agreement includes customary representations and covenants, and outlines termination rights if the acquisition does not close by July 12, 2027.
- : SEC 8-K (2.05): On August 5, 2026, the Company announced a targeted consolidation plan to consolidate existing manufacturing and distribution for formulated chemistries into a new Center of Excellence in North Carolina. This strategic move aims to enhance innovation, expand capacity, and optimize the U.S. chemistries manufacturing and distribution network. The plan anticipates the closure of facilities in St. Louis, Missouri, and Plymouth, Minnesota, with expected total pre-tax restructuring charges of approximately $55 million to $70 million, which will involve both cash expenditures and non-cash charges. Cash costs, estimated at $40 million to $50 million, include associate retention, severance, and other related expenses. This restructuring is expected to span several years, with completion anticipated by fiscal 2030.
- : SEC 8-K (5.02): On May 1, 2026, Richard C. Breeden notified STERIS plc that he will not stand for reelection to the Board of Directors. His retirement is not due to any disagreements with the Company. On May 5, 2026, the Board appointed Pierre Boulud, the CEO of bioMérieux, to fill the newly created tenth position on the Board. Boulud will receive a prorated fee of $76,989 for his role, payable in restricted stock units. His extensive background includes roles at bioMérieux and Ipsen, and he began his career as a strategic consultant. This change in directorship is significant as it reflects continuity and renewed leadership within the Company.
- : SEC 8-K (5.02): On March 31, 2026, STERIS plc and Michael J. Tokich, the former Chief Financial Officer, amended the Transition Agreement dated August 5, 2025. The Amendment extends Mr. Tokich's employment as a senior financial advisor on a part-time basis from April 1, 2026, through March 31, 2027. His annual salary will be reduced to $60,000, and while he will be eligible for a discretionary cash bonus, he will no longer receive benefits under the Company's health and dental plans, life insurance, or any other employee benefits. The Amendment is significant as it outlines the financial terms and changes in Mr. Tokich’s role, reflecting a shift in the Company's leadership structure during this transitional period.
- : SEC 8-K (5.02): On March 31, 2026, STERIS plc announced an amendment to the Transition Agreement with its former Chief Financial Officer, Michael J. Tokich. This Amendment outlines changes to the compensation and benefits that Mr. Tokich will receive following his transition from executive to advisory roles within the company. The original Agreement was established on August 5, 2025, and this recent amendment will alter the terms of his post-employment benefits. The changes aim to provide clarity and align Mr. Tokich's compensation with the company's current financial strategy after his departure from the executive position.
- : Steris Corporation Wins Contract Valued at $1.1 million
- : 1394436.38 USD Award for Steris Corporation
Leadership
- Marjorie, Vice President Processing Optimization and Customer Success
- Tara, Senior Talent Acquisition Partner
- Brian, Sr. Talent Acquisition Partner, Sales
Verified email and direct lines for STERIS plc’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
STERIS plc files 8 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
STERIS plc in the news
- Steris doubles down on healthcare consumables with $2.1 billion Xodus buy - Reuters (Oct 12, 2026)
- Steris (STE) Stock After Q4 Miss And 2027 Outlook What The Valuation Signals Now - Yahoo Finance (Jun 11, 2026)
- Medical equipment company to close St. Louis-area plant as it moves work to new $600M facility in NC - The Business Journals (Aug 06, 2026)
- Steris to sell dental segment for $787.5M - MedTech Dive (Apr 11, 2024)
- Steris inks $2.1B Xodus buyout to expand consumables portfolio - MedTech Dive (Oct 13, 2026)
- Are Options Traders Betting on a Big Move in STERIS Stock? - Yahoo Finance (Jun 09, 2026)
- STERIS plc (STE) Company Information - Simply Wall Street (Aug 08, 2022)
- STERIS (NYSE:STE) - Stock Analysis - Simply Wall St (Dec 01, 2017)
Companies similar to STERIS plc
- Food and Drug Administration · Biotechnology, Health Care
- Conagra Brands · Biotechnology, Health Care
- National Institutes of Health · Biotechnology, Health Care
- Regeneron · Biotechnology, Health Care
- Intuitive Surgical · Biotechnology, Health Care
About STERIS plc: questions and answers
What does STERIS plc do?
STERIS plc is a global leader in providing infection prevention and other procedural products and services. The company focuses on improving patient outcomes and healthcare efficiency. With its wide range of innovative solutions, STERIS serves various markets, including healthcare and pharmaceutical industries.
Where is STERIS plc headquartered?
STERIS plc is headquartered in Mentor, Ohio, United States.
How many employees does STERIS plc have?
STERIS plc has about 18,000 employees.
Who leads STERIS plc?
Marjorie is a Vice President Processing Optimization and Customer Success at STERIS plc.
What is the latest news on STERIS plc?
On Nov 04, 2026, SEC 8-K (2.05):
Is STERIS plc a public company?
Yes. STERIS plc is publicly traded under the ticker STE.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy